Brief: Hikma Says Demand In Middle East Region Remains Robust & Group Continues To Maintain Sufficient Inventory Levels
23/04/2026 07:22
April 23 (Reuters) - Hikma Pharmaceuticals PLC HIK.L: HIKMA PHARMACEUTICAL - TRADING STATEMENT HIKMA - REITERATES FULL YEAR 2026 GUIDANCE HIKMA - EXPECTS 2026 GROUP REVENUE TO GROW 2%-4% AND OPERATING PROFIT $720 MILLION-$770 MILLION HIKMA - TO WIND DOWN 503B COMPOUNDING BUSINESS HIKMA: WE ARE MONITORING EVOLVING GEOPOLITICAL SITUATION IN MIDDLE EAST HIKMA: DEMAND IN MIDDLE EAST REGION REMAINS ROBUST AND GROUP CONTINUES TO MAINTAIN SUFFICIENT INVENTORY LEVELS TO MITIGATE POTENTIAL SUPPLY CHAIN DISRUPTIONS HIKMA - EXECUTING SHARE BUYBACK PROGRAMME UP TO $250 MILLION; PURCHASED 4,374,095 SHARES FOR £54.8 MILLION HIKMA - PROPOSES FINAL DIVIDEND OF 48 CENTS PER SHARE, TOTAL 2025 DIVIDEND 84 CENTS, UP 5% Source text: ID:nRSW5560Ba Further company coverage: HIK.L (((( Reuters.Briefs@thomsonreuters.com ;));))